期刊文献+

不同配比的头孢噻肟-舒巴坦对产酶菌感染小鼠的体内抗菌作用 被引量:4

Antibacterial activities of different concentration ratio of cefotaxim-sulbactam against the pathogenic microorganisms
下载PDF
导出
摘要 目的:评价不同质量配比的头孢噻肟-舒巴坦的体内抗菌活性,为寻找其合理配比提供依据。方法:小鼠腹腔注射0.5 mL的1个最小致死量(MLD)菌液(金葡球菌、大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌)建立败血症模型,感染1 h后注射给予0.2 mL不同浓度的药液(每种药物配比5~6组,每组10只鼠),观察和记录感染鼠死亡率(共7 d)。用NDST软件程序的Bliss法计算半数有效量(ED_(50))值和95%有效量(ED_(95))值、ED_(50)的95%可信限,用t检验比较各药ED_(50)值。结果:头孢噻肟-舒巴坦在1:1,2:1和4:1质量配比时对大肠埃希菌、肺炎克雷伯菌产超广谱β内酰胺酶(ESBLs)菌株的体内抗菌作用显著优于头孢噻肟-舒巴坦(8:1)及头孢噻肟单剂,ED_(50)值及ED_(95)值仅为头孢噻肟单剂的1/6.6~1/2.0及1/6.9~1/1.4(P<0.01)。头孢噻肟-舒巴坦在1:1和2:1配比时对产酶阴沟肠杆菌感染小鼠体内抗菌作用优于4:1和8:1配比及头孢噻肟单剂,ED_(50)值及ED_(95)值仅为头孢噻肟单剂1/5.2~1/4.2及1/3.6~1/2.0(P<0.01)。头孢噻肟-舒巴坦在1:1,2:1,4:1和8:1配比时对产酶金葡球菌感染小鼠体内抗菌作用与头孢噻肟单剂相似。结论:头孢噻肟-舒巴坦在1:1和2:1配比时对大肠埃希菌、肺炎克雷伯ESBLs菌株及产酶阴沟肠杆菌感染小鼠体内抗菌作用最强。头孢噻肟-舒巴坦2:1配比可减少舒巴坦用药量,为最佳配方组合。 Objective:To evaluate the in vivo antibacterial effects of combination of sulbactam with cefotaxim (1: 1, 2: 1,4:1 and 8:1 ) in the treatment of mice septicemia caused by the pathogenic microorganisms producing extended-speetrum beta-lactamases(ESBLs). Methods: A mouse septicemia model was set up by an abdominal injection with 0. 5 mL minimum lethal dose of methicillin-resistant Staphylococcus aureus( MRSA ) ,Escherichia coli ( E. coli ) ,Klebsiella pneumoniae( Kl. pneumoniae ) and Enterobacter cloacae (Ent. cloacae). The different concentrations of combination antibiotics (0.2 mL each injection) were injected once into the mice in 1 hour after the injection of bacteria. Each combination antibiotics were tested in 5 -6 concentration groups, and each group was consisted of 10 mice. The death rate in each infected mice group was monitored. The EDso ,ED95 and L95 were calculated using a bliss method of NDST software. The t test was used to determine the statistical significance of ED50. Results: The combination of cefotaxim with sulbactam at the ratio of 1: 1,2: 1 and 4:1 showed a superiority against E. coli,Kl, pneumoniae and Ent. cloacae to the one at 1 : 8 and cefotaxim alone, the ED 50 and ED 95 values of the combination of sulbactam with cefotaxim (1: 1, 2:1 and 4: 1) against the mouse septicemia by E. coli and Kl. pneumoniae were 1/6. 6 - 1/2. 0 and 1/6. 9 - 1/1.4 times of cefotaxim alone (P 〈0.01 ). The combination of sulbactam with cefotaxim (1:1 and 2:1 ) against the mouse septicemia by Ent. cloacae were 1/5.2 - 1/4.2 and 1/3.6 - 1/2. 0 times of the ones at the ratio of 4:1 and 8:1 and cefotaxim alone (P 〈 0. 01 ). The combination of sulbactam with cefotaxim (1: 1, 2: 1, 4:1 and 8: 1) against the mouse septicemia by MRSA showed no difference from cefotaxim alone (P 〉 0. 05 ). Conclusion: The combination of sulbactam with cefotaxim (1:1 and 1: 2) had the most potent antibacterial activity. In the viewpoint of the combination, the optimal ratio of sulbactam to cefotaxim is 1:2.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第4期269-273,共5页 Chinese Journal of New Drugs
关键词 头孢噻肟 舒巴坦 败血症模型 体内抗菌作用 超广谱Β内酰胺酶 cefotaxim sulbctam mouse septicemia model in vivo antibacterial activity extended-spectrum beta-lactamases
  • 相关文献

参考文献11

  • 1KLUGMAN KP, SAUNDERS J, KHOOSAL M, et al. In-vitro activity of cefepime against bacterial pathogens from hospitalized patients [J] . J Antimicrob Chemother, 1993,32(1):164-166.
  • 2RANDEGGER CC, KELLER A, IRLA M, et al. Contribution of natural amino acid substilutions in SHV extended-spectrumbeta-lactamases to resistance against various-lactams[J]. Antimicrob Agents Chemother, 2000,44(10):2759-2763.
  • 3YAN JJ, KO WC, TSAI SH, ETAL. Dissemination of A-M-3 and CMY-Z bcta-lactamases among clinical isolates of Escherichia coil in southern [J]. Taiwan Clin Microbiol,2000,38(12):4320-4325.
  • 4YUAN M, HALl., LM, HOOGKAMP-KORSTANJE J, et al.SHV-14, a novel beta-laetamases variant in Klebsiella pneumoniae isolates from Nijmegen, the Netherlands [J]. Antimicrob Agents Chemother ,2001,45(1):309-311.
  • 5MEDEIROS AA. Evolution and dissemination of β-lactamases ac-celerated by generations of β-lactaantibioticts [J]. Clin Infect Dis, 1997,24 (suppl 1):S19-S45.
  • 6上海市细菌耐药性监测协作组.上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2002,2(1):1-9. 被引量:241
  • 7SCHUMACHER H, SCHEIBEL J, MOLLER JK. Cross-resistance patterns among clinical isolates of Klebsie11a pneumoniae with decreased susceptibility to cefuroxime [J]. J Antimicrob Chemother,2000,46(2):215-221.
  • 8张婴元.细菌耐药趋势与抗感染治疗的若干问题[J].中华医学杂志,2001,81(1):2-4. 被引量:72
  • 9AMYES SG, MILES RS. Extended spectrum β-lactamases, the role of inhibitor in therapy [J]. J Antlmicrob Chemother, 1998,42(4):415-417.
  • 10林庆安,赖国祥,柳德灵.头孢美唑对肺炎克雷伯菌和大肠埃希菌的体外抗菌活性[J].中国抗感染化疗杂志,2002,2(4):235-237. 被引量:6

二级参考文献32

  • 1于守汎.头孢美唑[J].国外医药(抗生素分册),1995,16(4):259-264. 被引量:3
  • 2汪复.抗菌药物临床应用进展[J].中华传染病杂志,1996,14(1):36-40. 被引量:22
  • 3汪复,朱德妹,张婴元.上海部分医院细菌耐药性监测及其临床意义[J].中华传染病杂志,1996,14(3):148-151. 被引量:101
  • 4斯崇文,田庚善.头孢美唑临床应用的评价[J].中华内科杂志,1996,35(10):668-672. 被引量:8
  • 5Ohya S,Fukuoka T,Masuda N,et al.Microbiological evaluation of panipenem/betamipron,a new parenterally active carlapenem V.increase in susceptibility of pseudomonas aeruginosa to panipenem in low.amino-acid media.Chemo Therapy,1991,39(S-3):132
  • 6Levy SB.The Challenge of antibiotic resistance[J].Scientific American,1998,278:46-53
  • 7Jones RN,Pfaller MA.Bacterial resistance: A worldwide problem[J].Diagn.Microbiol Infect Dis,1998,31:379-388
  • 8Williams RJ,Ryan MJ.Surveillance of antimicrobial resistance-an international perspective[J].Br Med J,1998,317:651
  • 9Am Society Microbiol.Report of the ASM task force on antibiotic resistance[J].Antimicrob Agents,Chemother,1995,Supplement: 1-23
  • 10World Health Organization.WHO global strategy for containment of antimicrobial resistance.WHO/CDS/CSR/DRS/2001.2[J]

共引文献315

同被引文献75

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部